Approval on a knife edge.
Michael
M
Eisenstein
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D017326:Clinical Trials, Phase III as Topic / Q000639:trends; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D000069283:Rituximab; D059039:Standard of Care / Q000639:trends
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C511911:belimumab